(Reuters) - Eli Lilly, Vir Biotech and partner GlaxoSmithKline said on Monday Lilly’s antibody therapy in combination with Vir’s antibody drug candidate reduced viral load in low-risk COVID-19 patients in a mid-stage trial.
The trial is testing Lilly’s bamlanivimab given in combination with Vir/GlaxoSmithKline’s VIR-7831.
Reporting by Manojna Maddipatla in Bengaluru; Editing by Sriraj Kalluvila
"load" - Google News
March 29, 2021 at 07:50PM
https://ift.tt/31uSGmk
Lilly-Vir's COVID-19 antibody combo reduced viral load in study - Reuters
"load" - Google News
https://ift.tt/2SURvcJ
https://ift.tt/3bWWEYd
Bagikan Berita Ini
0 Response to "Lilly-Vir's COVID-19 antibody combo reduced viral load in study - Reuters"
Post a Comment